Manufacturing Intelligence — July 22, 2026
|
Trump’s phased tariff plan — 100% on imported generic drugs from August 2028, doubling to 200% in August 2029 — gives a segment that supplies 90% of U.S. prescriptions a two-year reshoring window that no greenfield API plant can realistically be built inside.
Today’s top developments:
|
What to Watch
- Congressional and industry response to generic tariff phasing: Watch for formal comment periods, trade association filings from the Association for Accessible Medicines (AAM), and Congressional scrutiny of drug shortage risk as the 100%/200% tariff framework moves from Truth Social announcement toward formal regulatory action. The details of implementation — product scope, country-of-origin rules, and API vs. finished dose applicability — will determine the actual supply chain impact and should be tracked closely in USTR and Commerce Department rulemaking dockets over the next 60–90 days.
- Samsung Biologics U.S. site announcement: Samsung Biologics has signaled interest in establishing U.S. manufacturing presence as sponsor demand for domestic supply chain optionality grows. Given the tariff environment and political pressure on CDMOs to build American, a formal U.S. site announcement — either greenfield or via acquisition — would be a landmark competitive event for the large-molecule biologics CDMO market. Watch Samsung’s Q2 2026 earnings commentary and any follow-on analyst day presentations for signals.
- ADC CDMO capacity race intensifying: With the Mabion-KriSan deal and ongoing pipeline expansion across multiple sponsors, the ADC manufacturing capacity market is approaching an inflection point. Monitor whether established ADC CDMOs (Lonza, Catalent/Novo, Samsung Biologics’ ADC unit, Abzena) announce additional capacity investments or whether the partnership model exemplified by the Mabion-KriSan MSA becomes the dominant framework for managing ADC manufacturing supply as demand continues to outpace purpose-built infrastructure.
This brief highlights the edition’s top stories. Read the full July 22, 2026 edition → for all stories and analysis — or browse the Manufacturing Intelligence archive.